Teva Pharmaceutical Industries Limited (TEVA) — Analyst outlook / Analyst consensus target is. Based on 46 analyst ratings, the consensus is bullish — 22 Buy, 20 Hold, 4 Sell.
The consensus price target is $38.33 (low: $35.00, high: $41.00), representing an upside of 20.6% from the current price $31.77.
Analysts estimate Earnings Per Share (EPS) of $0.67 and revenue of $4.46B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.45 vs est $0.67 (missed -315.9%). 2025: actual $1.23 vs est $0.71 (beat +72.6%). Analyst accuracy: 6%.
TEVA Stock — 12-Month Price Forecast
$38.33
▲ +20.65% Upside
Average Price Target
Based on 46 Wall Street analysts offering 12-month price targets for Teva Pharmaceutical Industries Limited, the average price target is $38.33, with a high forecast of $41.00, and a low forecast of $35.00.
The average price target represents a +20.65% change from the last price of $31.77.
Highest Price Target
$41.00
Average Price Target
$38.33
Lowest Price Target
$35.00
TEVA Analyst Ratings
Buy
Based on 46 analysts giving stock ratings to Teva Pharmaceutical Industries Limited in the past 3 months
EPS Estimates — TEVA
6%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1.45
vs Est $0.67
▼ 146.3% off
2025
Actual $1.23
vs Est $0.71
▲ 42.0% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. EPS trend is improving. Analysts forecast meaningful EPS growth ahead.
Revenue Estimates — TEVA
27%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $16.544B
vs Est $4.457B
▲ 73.1% off
2025
Actual $17.257B
vs Est $4.578B
▲ 73.5% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
